Aimmune Therapeutics Priced, Nasdaq: AIMT

Developing an oral immunotherapy to desensitize peanut allergies.

Industry: Health Care

Latest Trade: $26.00 +0.44 (+1.7%)

First Day Return: +50.6%

Return from IPO: +59.8%

Industry: Health Care

We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. It is estimated that over 30 million people in the United States and Europe have a food allergy, with peanut allergy being the most prevalent and most commonly associated with severe outcomes and life-threatening events. Our therapeutic approach, which we refer to as Characterized Oral Desensitization Immunotherapy, or CODIT, is a system designed to desensitize patients to food allergens using rigorously characterized biologic products, defined treatment protocols and tailored support services. In ARC001, our recently completed Phase 2 study of our lead CODIT product candidate, AR101, all of the 23 patients who completed the AR101 treatment regimen were desensitized to a clinically meaningful level of peanut protein of at least 443 mg, a level that substantially exceeds the amount of peanut protein typically encountered in an accidental exposure, which we believe to be approximately 100 mg or less. Our ARC002 study, an open label Phase 2 follow on study of patients who participated in ARC001, is ongoing. We intend to initiate a Phase 3 registration trial of AR101 and Phase 2 studies of other CODIT product candidates for two additional food allergies in 2016. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation by the U.S. Food and Drug Administration and, if our planned Phase 3 trial is successful, we intend to file a Biologics License Application with the FDA and a Marketing Authorization Application with the European Medicines Agency. We have worldwide commercial rights to all of our product candidates and, if approved, we intend to commercialize in the United States and Europe with our own specialty sales force.
more less
IPO News for Aimmune Therapeutics
more
IPO Data
IPO File Date 07/06/2015
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.0
Deal Size ($mm) $160
IPO Data
IPO Date 08/05/2015
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.0
Deal Size ($mm) $160
Underwriters
more
Company Data
Headquarters Brisbane, CA
Founded 2011
Employees 21
Website www.aimmune.com